Azitra has been awarded a SBIR Grant to support development of a microbiome therapeutic for Netherton Syndrome, an orphan skin disease

…NS is extremely rare, it is a severe and unmet need…

“I’m thrilled to receive this funding and am honored to be joined by Dr. Julia Oh at JAX for this research,” said Travis Whitfill, MPH, Founder and Chief Scientific Officer, Azitra. “Although NS is extremely rare, it is a severe, unmet need and patients are desperate for new treatment options. We hope to bring forward a novel, microbe-based therapy, AZT-02, to deliver missing proteins as a viable therapeutic strategy. This project demonstrates the versatility and importance of our microbe-based platform to deliver proteins to the skin.”

Azitra’s Chief Scientific Officer, Travis Whitfill and The Jackson Laboratory’s (JAX) skin microbiome expert, Julia Oh, are the principal investigators on this SBIR grant.

 

 

Photo by Helloquence on Unsplash